Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trialSabine C A Meijvis, Douwe H. Biesma, Henrik Endeman et al.|The Lancet|2011Cited by 372
Addition of Vitamin D Status to Prognostic Scores Improves the Prediction of Outcome in Community-Acquired PneumoniaHilde H.F. Remmelts, Ger T. Rijkers, E.M.W. van de Garde et al.|Clinical Infectious Diseases|2012Cited by 74
Dexamethasone Downregulates the Systemic Cytokine Response in Patients with Community-Acquired PneumoniaHilde H.F. Remmelts, Ger T. Rijkers, Sabine C A Meijvis et al.|Clinical and Vaccine Immunology|2012Cited by 62
Treatment with anti‐inflammatory drugs in community‐acquired pneumoniaSabine C A Meijvis, Willem Jan W. Bos, E.M.W. van de Garde et al.|Journal of Internal Medicine|2012Cited by 48
Biomarkers define the clinical response to dexamethasone in community-acquired pneumoniaHilde H.F. Remmelts, Douwe H. Biesma, Sabine C A Meijvis et al.|Journal of Infection|2012Cited by 34